Literature DB >> 23291395

External validation of a novel transthoracic echocardiographic tool in predicting left atrial appendage thrombus formation in patients with nonvalvular atrial fibrillation.

Rami Doukky1, Abha Khandelwal, Enrique Garcia-Sayan, Heather Gage.   

Abstract

BACKGROUND: A recent study demonstrated that in patients with nonvalvular atrial fibrillation (AF), a ratio of left ventricular ejection fraction (LVEF) to the left atrial volume index (LAVI) of <1.5 has 100% sensitivity for detecting left atrial appendage (LAA) thrombus. We sought to validate this prediction tool in an external cohort.
METHODS: We conducted a cohort study of consecutive AF patients who underwent transoesophageal echocardiogram (TEE) to 'rule-out' LAA thrombus and had a prior transthoracic echocardiogram (TTE). The LAVI and LVEF were measured to calculate LVEF/LAVI ratio. The sensitivity and specificity of LVEF/LAVI <1.5 were calculated.
RESULTS: Among 215 subjects, 19 (8.8%) had LAA thrombus and also had a higher mean CHADS2 score (2.5 vs. 1.9, P = 0.04), lower mean LVEF (24 vs. 44%, P < 0.001), higher mean LAVI (44 mL/m2 vs. 30 mL/m2, P < 0.001), and higher prevalence of cardiac failure (79 vs. 52%, P = 0.02). The LVEF and LAVI were found to be independent predictors of LAA thrombus (P < 0.05). The LVEF/LAVI ratio diagnosed LAA thrombus with an area under the curve = 0.83 by the receiver operator characteristics curve analysis (P < 0.001). All 19 (100%) subjects with LAA thrombus had LVEF/LAVI <1.5 vs. 87 (44%) among those without LAA thrombus (P < 0.001). The sensitivity and specificity of LVEF/LAVI <1.5 were 100 and 55.6%, respectively.
CONCLUSION: This investigation validates a simple TTE prediction rule to exclude the diagnosis of LAA thrombus, which may obviate the need for pre-cardioversion TEE in selected patients with nonvalvular AF.

Entities:  

Keywords:  Atrial fibrillation; Ejection fraction; Left atrial appendage thrombus; Left atrial volume; Transoesophageal echocardiogram (TEE); Transthoracic echocardiogram (TTE)

Mesh:

Year:  2013        PMID: 23291395     DOI: 10.1093/ehjci/jes313

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  6 in total

Review 1.  Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options.

Authors:  Sérgio Barra; Simon Fynn
Journal:  J Saudi Heart Assoc       Date:  2014-09-03

2.  The value of diastolic function parameters in the prediction of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.

Authors:  Rami Doukky; Enrique Garcia-Sayan; Heather Gage; Vijaiganesh Nagarajan; Anna Demopoulos; Marek Cena; Noreen T Nazir; George J Karam; Richard G Trohman; Rasa Kazlauskaite
Journal:  Cardiovasc Ultrasound       Date:  2014-02-25       Impact factor: 2.062

3.  Relation between left atrial measurements and thromboembolic risk markers assessed by echocardiography in patients with nonvalvular atrial fibrillation: A cross-sectional study.

Authors:  Hanan I Radwan
Journal:  Egypt Heart J       Date:  2016-06-16

Review 4.  Diagnosis and Management of Left Atrium Appendage Thrombosis in Atrial Fibrillation Patients Undergoing Cardioversion.

Authors:  Enrico Melillo; Giuseppe Palmiero; Adele Ferro; Paola Elvira Mocavero; Vittorio Monda; Luigi Ascione
Journal:  Medicina (Kaunas)       Date:  2019-08-21       Impact factor: 2.430

5.  Prevalence of left atrial appendage thrombus in patients with acute ischaemic stroke and sinus rhythm: a cross-sectional study.

Authors:  Huan Thanh Nguyen; Hai Van Be Nguyen; Huy Quang Nguyen; Hung Quoc Le
Journal:  BMJ Open       Date:  2021-12-17       Impact factor: 2.692

6.  Impact of B-type natriuretic peptide level on the risk of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation: a prospective study.

Authors:  Rojina Pant; Mita Patel; Enrique Garcia-Sayan; Marwan Wassouf; Oliver D'Silva; Richard F Kehoe; Rami Doukky
Journal:  Cardiovasc Ultrasound       Date:  2016-01-16       Impact factor: 2.062

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.